8-Propan-2-yl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 8-Propan-2-yl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine
• 英文别名: 8-propan-2-yl-2,3-dihydro-[1,4]dioxino[2,3-b]pyridine
• 化学式: C₁₀H₁₃NO₂
• 分子量: 179.22
• InChiKey: LXMBKPMMXLCQGB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Boron-Containing Diacylhydrazines
  申请人：Intrexon Corporation

  公开号：US20150322092A1

  公开（公告）日：2015-11-12

  The present disclosure provides boron-containing diacylhydrazines having Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , and R 5 are defined as set forth in the specification. The present disclosure also provides the use of boron-containing diacylhydrazines is ecdysone receptor-based inducible gene expression systems. Thus, the present disclosure is useful for applications such as gene therapy, treatment of disease, large scale production of proteins and antibodies, cell-based screening assays, functional genomics, proteomics, metabolomics, and regulation of traits in transgenic organisms, where control of gene expression levels is desirable.

  本公开提供具有I式的含硼二酰肼化合物及其药学上可接受的盐和溶剂化物，其中R1、R2、R3、R4和R5的定义如规范中所述。本公开还提供了使用含硼二酰肼化合物的ecdysone受体基础的诱导基因表达系统。因此，本公开适用于基因治疗、疾病治疗、大规模生产蛋白质和抗体、基于细胞的筛选测定、功能基因组学、蛋白质组学、代谢组学和调控转基因生物的特征等应用，其中需要控制基因表达水平。
• DNA-PK INHIBITORS
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：EP3459942A1

  公开（公告）日：2019-03-27

  The present invention relates to compounds useful as inhibitors of DNA-PK. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

  本发明涉及可用作 DNA-PK 抑制剂的化合物。本发明还提供了包含所述化合物的药学上可接受的组合物，以及使用该组合物治疗各种疾病、病症或失调的方法。
• US20140256706A1
  申请人：——

  公开号：US20140256706A1

  公开（公告）日：2014-09-11
• US20140274954A1
  申请人：——

  公开号：US20140274954A1

  公开（公告）日：2014-09-18
• BET BROMODOMAIN INHIBITORS AND THERAPEUTIC METHODS USING THE SAME
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20170281773A1

  公开（公告）日：2017-10-05

  Inhibitors of BET bromodomains and compositions containing the same are disclosed. Methods of using the BET bromodomain inhibitors in the treatment of diseases and conditions wherein inhibition of BET bromodomain provides a benefit, like cancers, also are disclosed.